• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Brexpiprazole Intermediate CAS:70500-72-0
Brexpiprazole CAS:913611-97-9
3-BROMOPHENANTHRENE
2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE
3-BROMO-4-FLUOROBIPHENYL
9-TRIFLUOROACETYLANTHRACENE

DRL gets EIR from US FDA

expressbpdApril 11, 2018

Tag: DRL , FDA

Dr Reddy’s Laboratories (DRL) has received establishment inspection report from the US health regulator for its Cuernavaca facility in Mexico. The company had earlier said in a regulatory filing that audit of its active pharmaceutical ingredient (API) Cuernavaca plant in Mexico by the United States Food and Drug Administration (US FDA) was completed with zero observations.

"…we have received an Establishment Inspection Report (EIR) from the US FDA, for the above-referred facility," DRL said in a filing to the BSE. As per the US FDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.

Register as Visitor to CPhI China 2018!

Previous:Antibiotics may treat drug-resistant bacterial infections

Next:RMB 5.741 Billion to Raise! The Second Unicorn This Year—CRO Dominant Wuxi AppTec to be Listed on Shanghai Stock Exchange

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

DRL gets EIR from US FDA | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Ramantadine( FDA)

Ramantadine( FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service